Company Overview
AdaptHealth Corp., together with its subsidiaries, distributes home medical equipment (HME), medical supplies, and home and related services in the United States. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments. The company offers sleep therapy equipment, supplies, and related services, such as continuous positive airway pressure and BiLevel services to individuals suffering from obstructive sleep apnea; oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services; and medical devices, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; and other HME devices and supplies. It also provides PAP machines, wheelchairs, hospital beds, oxygen concentrators, ventilators, insulin pumps, diabetes management and wound care supplies, orthopedic bracing, breast pumps and supplies, walkers, commodes, enteral supplies, and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. AdaptHealth Corp. was founded in 2012 and is headquartered in Conshohocken, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 45.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $3.24B (-0.5% YoY); net profit $-70.79M.
- Trailing 12 Months Year-on-year growth — revenue +12.7%, earnings -178.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 45.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 45.27% |
| 1 Year: | 12.70% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -178.29% |
Stock Price Performance
| 1 Year: | -33.44% |
| 6 Months: | -31.61% |
| 3 Months: | -34.38% |
| 1 Month: | +7.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 45.3% over 5 years.
CONS
- Trading 51.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AHCO AdaptHealth Corp. R2KR3KPHARMA | 6.49 | -3.80 | $882.99M | 0.00% | 5.17% | -15.22% | 45.27% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 119.50M | 124.15M | 136.45M | 191.44M | 232.12M | 284.40M | 482.12M | 617.02M | 653.29M | 706.20M | 727.61M | 756.50M | 744.63M | 793.29M | 804.03M | 792.50M | 805.98M | - | - | 580.47M | 591.81M | 602.63M | 1.47B | 614.32M | 740.31M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 657.44M | 645.71M | 658.37M | 674.13M | 708.30M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -76.97M | -53.90M | -55.74M | 795.82M | -93.98M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -100.14M | -100.93M | -122.87M | 761.68M | -99.47M | - |
| Operating Income | -72.53K | -234.41K | -444.75K | 5.35M | 14.91M | 8.72M | 8.22M | 15.57M | 13.26M | 15.41M | 65.41M | 75.71M | 51.55M | 59.18M | 52.95M | 26.18M | 54.26M | -461.04M | 50.53M | 52.05M | - | - | 23.17M | 47.03M | 67.13M | 34.14M | 5.49M | -137.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 117.52M | 171.61M | 159.45M | 23.95M | 111.96M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.40M | 27.53M | 25.38M | 24.44M | 25.59M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.23M | 51.72M | 36.35M | -97.99M | -20.11M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 850.00K | 35.89M | 10.60M | 3.54M | -5.23M | - |
| Net Income | 220.33K | 689.83K | 518.32K | -5.80M | -2.08M | -3.69M | -34.55M | 4.47M | -51.03M | -3.97M | 79.11M | 58.09M | 41.75M | 14.03M | 16.12M | 15.71M | 13.98M | -454.08M | -2.13M | 19.43M | - | - | -7.21M | 14.67M | 24.51M | -102.77M | -16.04M | -133.93M |
| Diluted EPS | - | - | - | - | -0.10 | -0.17 | -0.82 | 0.08 | -0.89 | -0.08 | 0.12 | 0.20 | 0.08 | 0.09 | 0.11 | -0.06 | 0.09 | -3.43 | -0.02 | 0.13 | - | - | -0.05 | 0.10 | 0.16 | -0.76 | -0.12 | -0.99 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 345.28M | 529.64M | 1.06B | - | 2.97B | 3.20B | 3.26B | 3.24B |
| Cost of Revenue | - | - | - | - | 2.39B | 2.58B | 2.58B | 2.64B |
| Gross Profit | - | - | - | - | 580.12M | 624.07M | 681.09M | 609.20M |
| Operating Expenses | - | - | - | - | 389.70M | 391.68M | 404.28M | 422.93M |
| Operating Income | 31.09M | 29.38M | 71.35M | - | 190.41M | 232.39M | 276.81M | 186.27M |
| EBITDA | - | - | - | - | 558.49M | -210.70M | 628.02M | 472.53M |
| Interest Expense | - | - | - | - | 109.41M | 130.30M | 126.67M | 105.75M |
| Pretax Income | - | - | - | - | 97.90M | -723.78M | 136.02M | -15.15M |
| Tax Provision | - | - | - | - | 24.77M | -49.00M | 41.24M | 50.88M |
| Net Income | 23.26M | -21.34M | -161.63M | - | 69.32M | -678.89M | 90.42M | -70.79M |
| Diluted EPS | - | -0.95 | -3.08 | - | 0.33 | -5.31 | 0.61 | -0.52 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Nov 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 310.62K | 368.96M | 546.54M | 665.00M | 742.47M | 1.56B | 1.81B | - | 5.22B | 4.51B | 4.49B | 4.32B |
| Current Assets | - | - | - | - | - | - | - | - | - | 585.31M | 649.02M | 755.79M | 728.90M |
| Cash & Equivalents | - | 119.82K | 947.10K | - | - | - | - | - | - | 46.27M | 77.13M | 109.75M | 106.14M |
| Inventory | - | - | - | - | - | - | - | - | - | 127.75M | 113.64M | 139.84M | 151.25M |
| Receivables | - | - | - | - | - | - | - | - | - | 359.15M | 388.91M | 408.02M | 370.90M |
| Total Liabilities | - | 286.31K | 266.19M | 584.69M | 716.97M | 771.74M | 1.16B | 1.53B | - | 3.06B | 3.04B | 2.91B | 2.79B |
| Current Liabilities | - | 286.31K | 135.68M | 154.05M | - | - | - | 422.05M | - | 456.21M | 537.00M | 566.99M | 712.39M |
| Long Term Debt | - | - | 127.09M | 395.11M | - | - | - | 776.57M | - | 2.15B | 2.09B | 1.96B | 1.72B |
| Total Debt | - | - | - | - | - | - | - | - | - | 2.33B | 2.29B | 2.13B | 1.90B |
| Total Equity | 0 | 24.31K | 5.00M | -23.42M | -33.17M | -13.99M | 404.91M | 354.89M | - | 2.15B | 1.46B | 1.57B | 1.52B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 135.19M | 136.57M | 137.54M | 135.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 68.43M | 60.42M | 195.63M | - | 373.87M | 480.67M | 541.84M | 601.77M |
| Investing Cash Flow | -96.28M | -84.87M | -815.70M | - | -411.17M | -357.28M | -310.27M | -303.19M |
| Financing Cash Flow | 48.77M | 76.14M | 643.15M | - | -66.05M | -92.53M | -198.95M | -302.19M |
| Capital Expenditure | -9.95M | -21.33M | -39.76M | - | -391.42M | -337.46M | -306.06M | -382.39M |
| Free Cash Flow | 58.48M | 39.09M | 155.88M | - | -17.56M | 143.20M | 235.78M | 219.38M |
| Net Change in Cash | - | - | - | - | -103.36M | 30.86M | 32.62M | -3.61M |
| Share Buybacks | - | 20.00M | 0 | 0 | 13.99M | 29.27M | 0 | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 19.5% | 19.5% | 20.9% | 18.8% |
| Operating Margin % | 9.0% | 5.5% | 6.8% | - | 6.4% | 7.3% | 8.5% | 5.7% |
| Net Margin % | 6.7% | -4.0% | -15.3% | - | 2.3% | -21.2% | 2.8% | -2.2% |
| ROE % | 465.2% | 91.1% | -45.5% | - | 3.2% | -46.5% | 5.8% | -4.7% |
| ROCE % | 13.3% | 7.5% | 5.1% | - | 4.0% | 5.9% | 7.1% | 5.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | OEP Capital Advisors, LP | 11.96% | 16.31M | $94.45M |
| 2 | Blackrock Inc. | 11.78% | 16.06M | $93.00M |
| 3 | Deerfield Management Company, L.P | 8.42% | 11.48M | $66.46M |
| 4 | Skyknight Capital, L.p. | 6.29% | 8.58M | $49.68M |
| 5 | FMR, LLC | 5.78% | 7.88M | $45.64M |
| 6 | Dimensional Fund Advisors LP | 5.63% | 7.67M | $44.41M |
| 7 | Reinhart Partners, LLC | 5.44% | 7.42M | $42.94M |
| 8 | Vanguard Portfolio Management LLC | 4.71% | 6.43M | $37.21M |
| 9 | Vanguard Capital Management LLC | 3.55% | 4.84M | $28.04M |
| 10 | State Street Corporation | 3.40% | 4.63M | $26.83M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AHCO
Senior Health, Home Health & Hospice Stocks Q2 Recap: Benchmarking AdaptHealth (NASDAQ:AHCO)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how AdaptHealth (NASDAQ:AHCO) and the rest of the senior health, home heal…
5 Must-Read Analyst Questions From AdaptHealth’s Q2 Earnings Call
AdaptHealth’s second quarter results prompted a significant negative market reaction, as the company reported both revenue and profitability well below Wall Street’s expectations. Management attributed this to a combination of operational i…
AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript
CEO Foster discusses West Coast operational challenges and a $30M manufacturer price increase.
AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth
AdaptHealth (NASDAQ:AHCO) executives outlined the company’s second-quarter performance, portfolio changes and plans to focus capital on sleep, respiratory and home medical equipment businesses during a Canaccord conference discussion. Chief…
Why AdaptHealth Stock Plummeted This Week
AdaptHealth delivered news to investors this week that crushed its share price.
AdaptHealth Corp. to Participate in Upcoming Investor Conferences
CONSHOHOCKEN, Pa., August 07, 2026--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and rel…
AHCO — Frequently Asked Questions
What is the current share price of AdaptHealth Corp. (AHCO)?
As of 2026-09-07 16:24 PDT, AdaptHealth Corp. (AHCO) trades at $6.49 on NasdaqCM. Its 52-week range is $5.22 to $13.38.
What is the market capitalisation of AHCO?
AdaptHealth Corp. (AHCO) has a market capitalisation of $882.99M on NasdaqCM.
What is the P/E ratio of AHCO?
AHCO trades at a trailing price-to-earnings (P/E) ratio of -3.80. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.55.
What is the return on equity (ROE) of AHCO?
AHCO has a return on equity (ROE) of -15.22%. Its return on capital employed (ROCE) is 5.17%.
Is AHCO a good stock to buy?
This page provides a data-driven analysis of AdaptHealth Corp. (AHCO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.